230 related articles for article (PubMed ID: 32508015)
1. The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome.
Zheng BH; Ma JQ; Tian LY; Dong LQ; Song GH; Pan JM; Liu YM; Yang SX; Wang XY; Zhang XM; Zhou J; Fan J; Shi JY; Gao Q
Clin Transl Med; 2020 Jan; 10(1):45-56. PubMed ID: 32508015
[TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
3. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
[TBL] [Abstract][Full Text] [Related]
4. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular-cholangiocarcinoma: An analysis of clinicopathological characteristics after surgery.
Zhang H; Yu X; Xu J; Li J; Zhou Y
Medicine (Baltimore); 2019 Sep; 98(38):e17102. PubMed ID: 31567946
[TBL] [Abstract][Full Text] [Related]
7. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.
Lee JI; Lee JW; Kim JM; Kim JK; Chung HJ; Kim YS
World J Gastroenterol; 2012 Sep; 18(34):4751-7. PubMed ID: 23002345
[TBL] [Abstract][Full Text] [Related]
9. Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients.
Yang Y; Yang X; Wang Y; Xu J; Shen H; Gou H; Qin X; Jiang G
Front Immunol; 2022; 13():811007. PubMed ID: 35222387
[TBL] [Abstract][Full Text] [Related]
10. Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection.
Song P; Midorikawa Y; Nakayama H; Higaki T; Moriguchi M; Aramaki O; Yamazaki S; Aoki M; Teramoto K; Takayama T
Cancer Med; 2019 Oct; 8(13):5862-5871. PubMed ID: 31407490
[TBL] [Abstract][Full Text] [Related]
11. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma.
Kim SH; Park YN; Lim JH; Choi GH; Choi JS; Kim KS
Eur J Surg Oncol; 2014 Aug; 40(8):976-81. PubMed ID: 24909336
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
14. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
15. Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center.
Penzkofer L; Gröger LK; Hoppe-Lotichius M; Baumgart J; Heinrich S; Mittler J; Gerber TS; Straub BK; Weinmann A; Bartsch F; Lang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765596
[TBL] [Abstract][Full Text] [Related]
16. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
17. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
[TBL] [Abstract][Full Text] [Related]
18. Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy.
Yu J; Zhang X; Huang Q; Tan S; Xiong X; Gou H
Cancer Manag Res; 2021; 13():4283-4290. PubMed ID: 34113169
[TBL] [Abstract][Full Text] [Related]
19. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
